Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eran Harary

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Neuropsychiatric Disease and Treatment|October 14, 2024
TV-46000, A Long-Acting Subcutaneous Antipsychotic Agent, Demonstrated Improved Patient-Centered Outcomes in Patients with SchizophreniaLeslie Citrome, Mark Suett, Kelli R Franzenburg, et al.
CNS Drugs|July 2, 2024
A Long-Term Safety and Tolerability Study of TV-46000 for Subcutaneous Use in Patients with Schizophrenia: A Phase 3, Randomized, Double-Blinded Clinical TrialJohn M Kane, Roy Eshet, Eran Harary, et al.
The Lancet. Psychiatry|November 4, 2023
Efficacy and safety of TV-46000, a long-acting, subcutaneous, injectable formulation of risperidone, for schizophrenia: a randomised clinical trial in the USA and BulgariaJohn M Kane, Eran Harary, Roy Eshet, et al.
JAMA Network Open|October 5, 2021
Safety and Efficacy of Flexible-Dose Deutetrabenazine in Children and Adolescents With Tourette Syndrome: A Randomized Clinical TrialJoseph Jankovic, Barbara Coffey, Daniel O Claassen, et al.
Movement Disorders Clinical Practice|September 29, 2023
Safety and Efficacy of Long-Term Deutetrabenazine Use in Children and Adolescents with Tics Associated with Tourette Syndrome: An Open-Label Extension StudyJoseph Jankovic, Barbara Coffey, Daniel O Claassen, et al.
JAMA Network Open|October 18, 2021
Efficacy and Safety of Fixed-Dose Deutetrabenazine in Children and Adolescents for Tics Associated With Tourette Syndrome: A Randomized Clinical TrialBarbara Coffey, Joseph Jankovic, Daniel O Claassen, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Neuropsychiatric Disease and Treatment|October 14, 2024
TV-46000, A Long-Acting Subcutaneous Antipsychotic Agent, Demonstrated Improved Patient-Centered Outcomes in Patients with SchizophreniaLeslie Citrome, Mark Suett, Kelli R Franzenburg, et al.
CNS Drugs|July 2, 2024
A Long-Term Safety and Tolerability Study of TV-46000 for Subcutaneous Use in Patients with Schizophrenia: A Phase 3, Randomized, Double-Blinded Clinical TrialJohn M Kane, Roy Eshet, Eran Harary, et al.
The Lancet. Psychiatry|November 4, 2023
Efficacy and safety of TV-46000, a long-acting, subcutaneous, injectable formulation of risperidone, for schizophrenia: a randomised clinical trial in the USA and BulgariaJohn M Kane, Eran Harary, Roy Eshet, et al.
JAMA Network Open|October 5, 2021
Safety and Efficacy of Flexible-Dose Deutetrabenazine in Children and Adolescents With Tourette Syndrome: A Randomized Clinical TrialJoseph Jankovic, Barbara Coffey, Daniel O Claassen, et al.
Movement Disorders Clinical Practice|September 29, 2023
Safety and Efficacy of Long-Term Deutetrabenazine Use in Children and Adolescents with Tics Associated with Tourette Syndrome: An Open-Label Extension StudyJoseph Jankovic, Barbara Coffey, Daniel O Claassen, et al.
JAMA Network Open|October 18, 2021
Efficacy and Safety of Fixed-Dose Deutetrabenazine in Children and Adolescents for Tics Associated With Tourette Syndrome: A Randomized Clinical TrialBarbara Coffey, Joseph Jankovic, Daniel O Claassen, et al.
Pageof 2